| 0.2926 0 (0%) | 04-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.34 | 1-year : | 0.35 |
| Resists | First : | 0.29 | Second : | 0.3 |
| Pivot price | 0.29 | |||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.29 | MA(20) : | 0.29 |
| MA(100) : | 0.31  |
MA(250) : | 1.62 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.4 | D(3) : | 47.4 |
| RSI | RSI(14): 69.7 | |||
| 52-week | High : | 6.03 | Low : | 0.08 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENDP ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.31 - 0.31 | 0.31 - 0.31 |
| Low: | 0.28 - 0.28 | 0.28 - 0.28 |
| Close: | 0.29 - 0.29 | 0.29 - 0.3 |
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Sun, 21 Apr 2024
Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2% - Yahoo Movies Canada
Sun, 21 Apr 2024
Amneal Pharmaceuticals (AMRX) Jumps: Stock Rises 5.6% - Yahoo Movies Canada
Tue, 16 Aug 2022
Endo Creditors Eye Plan for Drugmaker's Sale Through Bankruptcy - Bloomberg
Tue, 09 Aug 2022
Endo International (ENDP) Stock Plunges Amid Bankruptcy Warning - InvestorPlace
Wed, 18 May 2022
Why Shares of Endo International Plummeted 69% on Wednesday - The Motley Fool
Thu, 10 Mar 2022
ENDP: Should You Scoop Up Shares of Endo International on the Dip? - StockNews.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 234 (M) |
| Shares Float | 199 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 41,450 (K) |
| Shares Short P.Month | 32,790 (K) |
| EPS | 0.78 |
| EPS Est Next Qtrly | 0.7 |
| EPS Est This Year | 3.51 |
| EPS Est Next Year | 3 |
| Book Value (p.s.) | -2.81 |
| Profit Margin | -24.9 % |
| Operating Margin | 24.7 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -9.2 % |
| Gross Profit (p.s.) | 7.61 |
| Sales Per Share | 12.53 |
| EBITDA (p.s.) | 3.05 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 369 (M) |
| Levered Free Cash Flow | 639 (M) |
| PE Ratio | 0.37 |
| PEG Ratio | -0.1 |
| Price to Book value | -0.11 |
| Price to Sales | 0.02 |
| Price to Cash Flow | 0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|